This invention relates to a composite probiotic designed to enhance the absorption of iron ions in the intestines and its various applications. The composite probiotic comprises Lactobacillus gasseri LG08 (CGMCC No. 16131) and Lactobacillus johnsonii LJ09 (CGMCC No. 20123).

The invention relates to a probiotic agent for degrading ethanol, including Lacticaseibacillus rhamnosus LRa66 and Lactiplantibacillus plantarum Lp90. These strains work synergistically to enhance ethanol degradation and alleviate alcohol-induced liver damage.

This invention relates to a probiotic preparation designed to regulate brain-derived neurotrophic factor (BDNF) and sex hormones.

Irritable Bowel Syndrome (IBS) is a prevalent functional gastrointestinal disorder affecting 10-20% of the global population, with IBS-C being a common subtype characterized by constipation symptoms such as straining, hard stools, and infrequent bowel movements.

The recent commissioning of Wecare's Phase III probiotic strain factory, boasting a remarkable production capacity of 600 tons, signifies a quantum leap in the company's production capabilities and scale of probiotic strains.

In a groundbreaking study published in Frontiers in Immunology, researchers from Tokyo University of Science have uncovered a potential mechanism by which gut bacteria can positively influence inflammatory bowel disease (IBD).